Cocrystal Pharma, Inc.
COCP
$1.04
$0.032.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5.47M | 7.76M | 10.95M | 12.54M | 14.77M |
| Gross Profit | -5.47M | -7.76M | -10.95M | -12.54M | -14.77M |
| SG&A Expenses | 4.30M | 4.96M | 5.11M | 5.34M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.77M | 12.72M | 16.06M | 17.88M | 20.31M |
| Operating Income | -9.77M | -12.72M | -16.06M | -17.88M | -20.31M |
| Income Before Tax | -9.67M | -12.56M | -15.85M | -17.50M | -18.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.67 | -12.56 | -15.85 | -17.50 | -18.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.67M | -12.56M | -15.85M | -17.50M | -18.70M |
| EBIT | -9.77M | -12.72M | -16.06M | -17.88M | -20.31M |
| EBITDA | -9.68M | -12.62M | -15.95M | -17.75M | -20.18M |
| EPS Basic | -0.94 | -1.23 | -1.56 | -1.72 | -1.84 |
| Normalized Basic EPS | -0.58 | -0.77 | -0.97 | -1.08 | -1.21 |
| EPS Diluted | -0.94 | -1.23 | -1.56 | -1.72 | -1.84 |
| Normalized Diluted EPS | -0.58 | -0.77 | -0.97 | -1.08 | -1.21 |
| Average Basic Shares Outstanding | 41.51M | 40.70M | 40.70M | 40.70M | 40.74M |
| Average Diluted Shares Outstanding | 41.51M | 40.70M | 40.70M | 40.70M | 40.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |